Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer

Prostate

Volumn 67, Issue 7, 2007, Pages 732-742

  Johanneson, Bo ^a   Deutsch, Kerry ^b   McIntosh, Laura ^c   Friedrichsen Karyadi, Danielle M ^c   Janer, Marta ^b   Kwon, Erika M ^a   Iwasaki, Lori ^c   Hood, Leroy ^b   Ostrander, Elaine A ^a   Stanford, Janet L ^c,d  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hereditary prostate cancer; Kidney cancer; Linkage analysis; Renal cancer

Indexed keywords

ARTICLE; CANCER FAMILY; GENE MAPPING; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; TRANSITIONAL CELL CARCINOMA;

AGED; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; LINKAGE (GENETICS); MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PEDIGREE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34248143042     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20528     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA: A Cancer J Clin 2006;56:106-130.
2. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK. SEER cancer statistics review, 1975-2003. Bethesda, MD: National Cancer Institute; 2005.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. New Engl J Med 2005;353(23):2477-2490.
4. Rabbani F, Reuter VE, Katz J, Russo P. Second primary malignancies associated with renal cell carcinoma: Influence of histologic type. Urology 2000;56(3):399-403.
5. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol Rev 2001;23(1):19-23.
6. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta-analysis. Cancer 2003;97(8):1894-1903.
7. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994;152(5 Pt 1): 1484-1487.
8. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: A study of World War II veteran twins. Prostate 1997;33:240-245.
9. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. New Engl J Med 2000;343(2):78-85.
10. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89(8):3367-3371.
11. Grönberg H, Damber L, Damber J-E, Iselius L. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance. Am J Epidemiol 1997;146(7):552-557.
12. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62:1425-1438.
13. Verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey-Wilson JE, Beaty TH, Catalona WJ, Kiemeney LA. Autosomal dominant inheritance of prostate cancer: A confirmatory study. Urology 2001;57(1):97-101.
14. Cui J, Staples MP, Hopper JL, English DR, McCredie MRE, Giles GG. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 2001;68(5):1207-1218.
15. Gong G, Oakley-Girvan I, Wu AH, Kolonel LN, John EM, West DW, Felberg A, Gallagher RP, Whittemore AS. Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes and Control 2002;13(5):471-482.
16. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin P, Berthon P, Cussenot O, Demenais F. Segregation analysis of prostate cancer in France: Evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann Hum Genet 2003;67(Pt 2):125-137.
17. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE. Evidence of an x-linked or recessive genetic component to prostate cancer risk. Nat Med 1995;1(8):827-829.
18. Narod SA, Dupont A, Cusan L, Diamond P, Gomez J-L, Suburu R, Labrie F. The impact of family history on early detection of prostate cancer. Nat Med 1995;1(2):99-101.
19. Ostrander EA, Friedrichsen DM. Genetic factors: Finding cancer susceptibility genes. 3rd edn: Elsevier Science; New York, NY, 2004, pp. 253-267.
20. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ, International Consortium for Prostate Cancer Genetics. Where are the prostate cancer genes? - A summary of eight genome wide searches. Prostate 2003;57(4):261-269.
21. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(1):R103-R121.
22. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King M-C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-1689.
23. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields, P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. Localization of a breast cancer susceptibility gene BRCA2, to chromosome 13q12-13. Science; 1994;265:2088-2090.
24. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999;64(3):776-787.
25. Badzioch M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar D, Hopper JL, Bishop DT, Moller P, Heimdal K, Easton D, Simard J. Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. Med Genet 2000; 37(12):947-949.
26. Janer M, Friedrichsen DM, Stanford JL, Badzioch MD, Kolb S, Deutsch K, Peters MA, Goode EL, Welti R, DeFrance HB, Iwasaki L, Li S, Hood L, Ostrander EA, Jarvik GP. Genomic scan of 254 hereditary prostate cancer families. Prostate 2003;57(4):309-319.
27. Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S, Deutsch K, Janer M, Hood L, Ostrander EA, Schaid DJ. Prostate cancer and genetic susceptibility: A genome scan incorporating disease aggressiveness. Prostate 2006;66(3):317-325.
28. Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters MA, Goode EL, Kolb S, Chakrabarti L, Shook M, Basom R, Ostrander EA, Hood L. A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet 2000;67(1):100-109.
29. O'Connell JR, Weeks DE. PedCheck: A program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259-266.
30. Wellcome Trust Center for Human Genetics. ftp://ftp.well.ox.ac.uk/pub/ genetics.
31. Boehnke M, Cox NJ. Accurate inference of relationships in sib-pair linkage studies. Am J Hum Genet 1997;61(2):423-429.
32. Sun L, Wilder K, McPeek M. Enhanced pedigree error detection. Hum Hered 2002;54(2):99-110.
33. Cook EH Jr. Merlin: Faster linkage analysis with improved genotyping error detection. Pharmacogenom J 2002;2(3):139-140.
34. Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci USA 1984;81: 3443-3446.
35. Cottingham RW Jr, Idury RM, Schaffer AA. Faster sequential genetic linkage computations. Am J Hum Genet 1993;53(1):252-263.
36. Schaffer AA, Gupta SK, Shriram K, Cottingham RW Jr. Avoiding recomputation in linkage analysis. Hum Hered 1994;44(4):225-237.
37. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL. Comprehensive human genetic maps: Individual and sex-specific variation in recombination. Am J Hum Genet 1998; 63(3):861-869.
38. Nievergelt CM, Smith DW, Kohlenberg JB, Schork NJ. Large-scale integration of human genetic and physical maps. Genome Res 2004;14(6):1199-1205.
39. Rozen S, Skaletsky H. Primer3 on the www for general users and for biologist programmers. Methods Mol Biol 2000;132:365-386.
40. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: A unified multipoint approach. Am J Hum Genet 1996;58(6):1347-1363.
41. Markianos K, Daly MJ, Kruglyak L. Efficient multipoint linkage analysis through reduction of inheritance space. Am J Hum Genet 2001;68:963-977.
42. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002;30(1):97-101.
43. Kong A, Cox NJ. Allele-sharing models: Lod scores and accurate linkage tests. Am J Hum Genet 1997;61(5):1179-1188.
44. Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, et al. A high-resolution recombination map of the human genome. Nat Genet 2002;31(3):241-247.
45. Gronberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, Bova GS, Danber JE, Bergh A, Walsh PC, Collins FS, Trent JM, Meyers DA, Isaacs WB. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997;57(21):4707-4709.
46. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C, Vonder Haar RA, Fair WR, Heston WD. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochimica Et Biophysica Acta 1998;1443(1-2):113-127.
47. Gronberg H, Bergh A, Damber J-E, Emanualsson M. Cancer risk in families with hereditary prostate carcinoma. Cancer 2000;89(6):1315-1321.
48. Vaittinen P, Hemminki K. Familial cancer risks in offspring from discordant parental cancers. Int J Cancer 1999;81:12-19.
49. Hemminki K, Chen B. Familial association of prostate cancer with other cancers in the Swedish family-cancer database. Prostate 2005;65:188-194.
50. Isaacs SD, Kiemeney LALM, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995;87(13):991-996.
51. Verhage BA, Aben KK, Witjes J A, Straatman H, Schalken JA, Kiemeney LA. Site-specific familial aggregation of prostate cancer. Int J Cancer 2004;109(4):611-617.
52. Albright LA, Schwab A, Camp NJ, Farnham JS, Thomas A. Population-based risk assessment for other cancers in relatives of hereditary prostate cancer (HPC) cases. Prostate 2005;64(4): 347-355.
53. Eldon BJ, Jonsson E, Tomasson J, Tryggvadottir L, Tulinius H. Familial risk of prostate cancer in Iceland. BJU Int 2003;92(9): 915-919.
54. Negri E, Pelucchi C, Talamini R, Montella M, Gallus S, Bosetti C, Franceschi S, La Vecchia C. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer 2005;114:648-652.
55. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K. Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family. PLoS Medicine/Public Library of Science 2004;1(3):e65.
56. Booker LM, Habermacher GM, Jessie BC, Sun QC, Baumann AK, Amin M, Lim SD, Fernandez-Golarz C, Lyles RH, Brown MD, Marshall FF, Petros JA. North American white mitochondrial haplogroups in prostate and renal cancer. J Urol 2006;175(2): 468-472; discussion 472-473.
57. Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, Goddard KA, Witte JS, Elston RC , Catalona WJ. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 2000;66(3):933-944.
58. Edwards S, Meitz J, Eles R, Evans C, Easton D, Hopper J, Giles G, Foulkes WD, Narod S, Simard J, Badzioch M, Mahle L, International ACTANE Consortium. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE Consortium. Prostate 2003;57(4):270-279.
59. Schleutker J, Baffoe-Bonnie AB, Gillanders E, Kainu T, Jones MP, Freas-Lutz D, Markey C, Gildea D, Riedesel E, Albertus J, Gibbs KD Jr, Matikainen M, Koivisto PA, Tammela T, Bailey-Wilson JE, Trent JM, Kallioniemi OP. Genome-wide scan for linkage in Finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate 2003; 57(4):280-289.
60. Rokman A, Baffoe-Bonnie AB, Gillanders E, Fredriksson H, Autio V, Ikonen T, Gibbs KD Jr, Jones M, Gildea D, Freas-Lutz D, Markey C, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Trent J, Bailey-Wilson JE, Schleutker J. Hereditary prostate cancer in Finland: Fine-mapping validates 3p26 as a major predisposition locus. Hum Genet 2005; 116(1-2):43-50.
61. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274(5291):1371-1374.
62. Jackson P, Ow K, Yardley G, Delprado W, Quinn DI, Yang JL, Russell PJ. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with P53 overexpression. Prostate Cancer & Prostatic Diseases 2003;6(2): 174-181.
63. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surgery 2006;30(4):628-636.
64. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-85.
65. Leach F. Targeting prostate-specific membrane antigen in cancer therapy: Can molecular medicine be brought to the surface? Cancer Biol Ther 2004;3(6):559-560.